Most Read Articles
Stephen Padilla, 06 Aug 2020
The novel coronavirus disease (COVID-19) pandemic appears to have a significant impact on oncological care, according to a study, which stresses the need for psycho-oncological support for cancer patients.
01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
06 Aug 2020
Sodium–glucose cotransporter-2 (SGLT-2) inhibitors increase the risk for diabetic ketoacidosis (DKA) by almost threefold, with molecule-specific analyses suggesting a class effect, according to a study.
Stephen Padilla, 3 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.

Electrical nerve stimulation helps mitigate movement-evoked pain in fibromyalgia

12 Jan 2020

Use of active transcutaneous electrical nerve stimulation (TENS) in fibromyalgia (FM) patients receiving treatment results in a favourable reduction in movement-evoked pain, according to the results of a trial.

The trial randomized female FM patients receiving steady medication to active TENS (n=103), placebo TENS (n=99) or no TENS (n=99). TENS was applied to the lumbar and cervicothoracic regions using a modulated frequency (2–125Hz) at the highest tolerable intensity, with patients instructed to use it at home 2h/day during activity for 4 weeks.

Movement‐evoked pain (primary outcome) and fatigue were rated on an 11‐point scale before and during application of TENS.

After 4 weeks, movement-evoked pain decreased significantly with active TENS vs placebo TENS (mean difference, –1.0, 95 percent confidence interval [CI], –1.8 to –0.2; p=0.008) and no TENS (mean difference, –1.8, 95 percent CI, –2.6 to –1.0; p<0.0001). The same was observed for fatigue (mean difference, –1.4, 95 percent CI, –2.4 to –0.4; p=0.001 and mean difference, –1.9, 95 percent CI, –2.9 to –0.9; p=0.0001, respectively).

Significantly more patients in the active‐TENS group reported improvement in the global impression of change than in the placebo‐TENS and no-TENS groups (70 percent vs 31 percent and 9 percent, respectively; p-both<0.0001).

There were no reports of TENS‐related serious adverse events, with <5 percent of the overall population experiencing minor adverse events with TENS.

Additional investigation is warranted to examine effectiveness in a real world, pragmatic setting to establish clinical importance of the present data, according to researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 06 Aug 2020
The novel coronavirus disease (COVID-19) pandemic appears to have a significant impact on oncological care, according to a study, which stresses the need for psycho-oncological support for cancer patients.
01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
06 Aug 2020
Sodium–glucose cotransporter-2 (SGLT-2) inhibitors increase the risk for diabetic ketoacidosis (DKA) by almost threefold, with molecule-specific analyses suggesting a class effect, according to a study.
Stephen Padilla, 3 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.